Metastatic Tumor Research and Outcomes Network
Launched by AO INNOVATION TRANSLATION CENTER · Jul 8, 2016
Trial Information
Current as of November 02, 2025
Recruiting
Keywords
ClinConnect Summary
The Metastatic Tumor Research and Outcomes Network is a clinical trial that focuses on gathering important information about patients with metastatic spine tumors. This means the study is looking at patients whose cancer has spread to the spine from another part of the body. Researchers want to learn more about the patients’ backgrounds, any other health conditions they may have, the treatments they receive, and how these factors affect their quality of life and any side effects they experience.
To be eligible for this study, participants must be at least 18 years old and have a confirmed diagnosis of a metastatic tumor in the spine. This study is open to everyone regardless of gender. Participants will need to provide informed consent, meaning they understand what the study involves and agree to take part. If you join the trial, you’ll be contributing valuable information that could help improve care and treatment for others with similar conditions. The study is currently recruiting participants, so if you or someone you know fits the criteria, it may be a great opportunity to get involved.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient 18 or older.
- • Patient diagnosed with a metastatic tumor of the spine
- * Informed consent obtained, i.e.:
- • Ability to understand the content of the patient information/ICF
- • Willingness and ability to participate in the registry according to the Registry Plan
- • Signed and dated EC/IRB approved written informed consent (if consent is required by the EC/ IRB at the registry site)
- Exclusion Criteria:
- • • Patient diagnosed with a primary tumor of the spine.
About Ao Innovation Translation Center
The AO Innovation Translation Center (AO ITC) is a leading clinical trial sponsor dedicated to advancing orthopedic research and innovation. With a focus on translating cutting-edge scientific discoveries into clinical applications, AO ITC collaborates with healthcare professionals, researchers, and industry partners to facilitate the development of novel therapies and technologies. By leveraging its extensive network and expertise, AO ITC aims to enhance patient care and outcomes in the field of musculoskeletal health, ensuring that innovative solutions are efficiently brought to market and accessible to those in need.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Utrecht, Netherlands
Montréal, Quebec, Canada
Vancouver, British Columbia, Canada
Budapest, Hungary
San Francisco, California, United States
Chicago, Illinois, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Rochester, Minnesota, United States
Rochester, New York, United States
Valhalla, New York, United States
Philadelphia, Pennsylvania, United States
Providence, Rhode Island, United States
Houston, Texas, United States
Clayton, Victoria, Australia
Winnipeg, Manitoba, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Dresden, Sachsen, Germany
Bologna, Emilia Romagna, Italy
Milano, Lombardei, Italy
Uchinoda, Ishikawa, Japan
Singapore, Singapore
Basel, Switzerland
Patients applied
Trial Officials
Charles G. Fisher, MD
Principal Investigator
Vancouver General Hospital and the University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials